Targeted therapies for lung cancer: how did the game begin?

Kanellakis Nikolaos I., Jacinto Tiago, Psallidas Ioannis

Source: Breathe 2016; 12: 177-179

Journal Issue: June

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Kanellakis Nikolaos I., Jacinto Tiago, Psallidas Ioannis. Targeted therapies for lung cancer: how did the game begin?. Breathe 2016; 12: 177-179

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Novel aspects in lung cancer pathology: how does it help for selecting chemotherapy? Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician Year: 2010
Stem cells and lung cancer treatment: any hope? Source: International Congress 2016 – Molecular footprints in lung cancer diagnosis and management Year: 2016
Targeted therapy for lung cancer Source: Eur Respir J 2015; 46: 1239-1241 Year: 2015
Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing? Source: Eur Respir J 2014; 44: 1011-1022 Year: 2014
Lung disease induced by newer therapies for lung cancer: an update Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006
Why can initial treatment of localised lung cancer fail? Source: Annual Congress 2007 - Recurrence of lung cancer following resection with curative intent Year: 2007
Can we expect progress from targeted therapy of SCLC? Source: Eur Respir Monogr 2015; 68: 234-246 Year: 2015
Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations Source: Eur Respir J 2015; 46: 19-21 Year: 2015
Precision medicine for lung cancer: new targeted treatments Source: International Congress 2017 – Precision medicine approaches in lung cancer Year: 2017
Current place and future of immunotherapy in lung cancer Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies? Year: 2016
Biomarkers in early-detection of lung cancer: current concepts Source: Virtual Congress 2021 – Biomarkers in early-detection of lung cancer: current concepts Year: 2021
The lung cancer microenvironment and the lung microbioma: cross or cease fire? Source: Virtual Congress 2020 – Exciting new developments in lung cancer screening, diagnostics and treatment Year: 2020
Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019
Lung cancer: does age affect treatment strategy? Source: Eur Respir Mon; 2009: 43:306–326 Year: 2009
ALK- and ROS-1-inhibition: a relevant treatment strategy for lung cancer? Source: International Congress 2014 – Update on lung cancer biology for clinicians Year: 2014
Advances in treatment of complex lung disease: will targeted therapy with anticalins be clinically applied in the near future? Source: International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments Year: 2019
Advances in target therapy in lung cancer Source: Eur Respir Rev 2015; 24: 23-29 Year: 2015
Advances in target therapy for lung cancer Source: International Congress 2014 – Ceremony for the ERS Romain Pauwels Research Award 2014 - Clinical Year in Review I Year: 2014